LEMAITRE VASCULAR INC SEC Filings

LMAT Form 144 notice reports a proposed sale of common stock by Morgan Stanley Smith Barney LLC Executive Financial Services, dated 05/07/2026.

The filing lists a Stock Option Exercise for 2,858 shares on 05/07/2026 and multiple equity award entries: 208, 203, 158, 140, 173, and 203 shares tied to grant or vesting dates in 12/2025 and 02/26/2026.

LeMaitre Vascular, Inc. reported solid first‑quarter 2026 growth with higher sales, margins, and earnings. Net sales rose to $66.6 million, up 11% from 2025, driven by grafts, valvulotomes, and shunts across all regions. Gross profit increased to $48.4 million and gross margin improved to 72.7%, helped by price increases, manufacturing efficiencies, and a more profitable product mix.

Net income grew to $15.7 million, up from $11.0 million, with diluted EPS at $0.68. The company generated $15.1 million of operating cash flow, ending the quarter with $26.9 million in cash and $340.4 million in short‑term marketable securities, alongside $172.5 million of 2.50% convertible senior notes due 2030.

LeMaitre increased its quarterly dividend to $0.25 per share and authorized a $100 million share repurchase program, while continuing to invest in global sales expansion, ERP implementation, and facility leases. Biologics represented 53% of sales, and international markets contributed 44% of net sales, aided by a weaker U.S. dollar and recent regulatory approvals.

LeMaitre Vascular, Inc. reported strong preliminary Q1 2026 results with net sales of $66.6M, up from $59.9M, driven by 11% sales growth and broad strength across products and regions. Artegraft sales grew 36% worldwide, while grafts, valvulotomes, and carotid shunts each set record sales.

Gross margin reached 72.7%, up 350 basis points, and operating income rose to roughly $17.8M, a 41% increase. Diluted EPS grew 42% in Q1. Management’s guidance implies full-year 2026 sales growth of 12% and adjusted EPS growth of 26%, with Q2 sales expected around $71.5M at the midpoint.

The board approved a quarterly dividend of $0.25 per share payable on June 4, 2026, and authorized a share repurchase program of up to $100M through February 18, 2027. The company also highlighted non-GAAP metrics such as adjusted EBITDA and organic sales growth.

LeMaitre Vascular director Joseph P. Pellegrino Jr. exercised stock options to acquire 2,941 shares of Common Stock at $35.48 per share. These shares came from a fully vested option that was exercised in full, leaving no remaining derivative position from this grant. Following the transaction, he directly owns 15,021 Common shares, making this a routine compensation-related option exercise rather than an open-market purchase or sale.

LeMaitre Vascular, Inc. is asking stockholders to vote at its 2026 annual meeting on June 2, 2026, in Burlington, Massachusetts. Investors will elect two Class II directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify Grant Thornton LLP as auditor for 2026.

The proxy highlights a seven‑member, largely independent board with extensive medical device and financial expertise, and describes governance practices such as a director resignation policy, clawback policy, insider trading restrictions, and board‑level risk oversight. It also discloses major shareholders and 2025 executive pay structure, which ties a significant portion of compensation to financial and operational performance.

LeMaitre Vascular, Inc. reports upcoming changes to its Board of Directors tied to the 2026 Annual Meeting of Stockholders on June 2, 2026. Bridget Ross, a Class II director, has informed the Board she will not stand for re-election and will serve until her current term ends at that meeting. The company states her decision is not due to any disagreement regarding operations, policies, or practices.

To rebalance the staggered board, the Board has nominated David B. Roberts to stand for election as a Class II director at the same meeting. In connection with this nomination, Mr. Roberts has indicated he will resign as a Class I director at the conclusion of the meeting, contingent on his election as a Class II director. After these changes, the Board will have seven members instead of eight, structured as two Class I directors, two Class II directors, and three Class III directors, consistent with the company’s charter and by-law provisions allowing the Board to set its own size.

LeMaitre Vascular director Martha Shadan reported equity-based compensation awards, not open-market trades. On March 26, 2026, she was granted several small blocks of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025.

Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying stock awards. All transactions are coded as awards or other acquisitions, with no reported share purchases or sales in the market.

LEMAITRE VASCULAR INC director Bridget A. Ross reported compensation-related awards of dividend equivalent rights tied to existing equity grants. On March 26, 2026, she acquired several small blocks of dividend equivalent rights, each economically equivalent to one share of common stock and linked to prior restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. These rights vest proportionately with the underlying awards and reflect routine equity compensation accruals rather than open-market trading.